|
Investor Relations
Press Releases
Events & Presentations
Corporate Governance
Financial Information
Stock Information
Investor FAQs
Contact Us
Shareholder Tools
Email Alerts
Search Investor Relations
|
Press Releases
All Releases
 |
Pharmasset Initiates Phase 1b Multiple Ascending Dose Clinical Trial of PSI-7851 in Chronic Hepatitis C Patients
Jun 9, 2009
|
11.9 KB |
|
| |
PRINCETON, N.J., June 9, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it had completed the single ascending dose study and begun dosing in a multiple ascending dose trial with PSI-7851, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C virus (HCV) infecti...
|
|
Pharmasset to Present at Goldman Sachs and Needham Healthcare Conferences
Jun 2, 2009
|
10.5 KB |
|
| |
PRINCETON, N.J., June 2, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Goldman Sachs Global Healthcare Conference and the Needham Healthcare Conference. Both conferences will be held in New York, NY.
Schaefer Price, Pharmasset's President and Chief Executive Officer,...
|
|
Pharmasset to Present at Deutsche Bank Healthcare Conference
May 14, 2009
|
10.5 KB |
|
| |
PRINCETON, N.J., May 14, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Deutsche Bank 34th Annual Healthcare Conference. The conference will be held in the InterContinental Boston Hotel, Boston, MA (May 18 to 19).
Schaefer Price, Pharmasset's President and Chief Execu...
|
|
Pharmasset Reports Fiscal Second Quarter 2009 Financial Results
May 11, 2009
|
17.0 KB |
|
| |
PRINCETON, N.J., May 11, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing, and commercializing novel drugs to treat viral infections, reported financial results and operational highlights for the fiscal quarter ended March 31, 2009.
...
|
|
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
Apr 25, 2009
|
24.9 KB |
|
| |
NUTLEY, N.J., BRISBANE, Calif., and PRINCETON, N.J., April 25, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Roche, InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) today announced the first results from their innovative, interferon-free regimen of direct acting antiviral (DAA) combination therapy for the treatment of patients ...
|
|
Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
Apr 24, 2009
|
20.7 KB |
|
| |
PRINCETON, N.J., April 24, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) and Roche (Roche SWX: RO, ROG; Pink Sheets: RHHBY) today announced that the first patient has been dosed in a Phase IIb study of R7128, the nucleoside polymerase inhibitor most advanced in development for the treatment of chronic hepati...
|
|
Pharmasset Voluntarily Halts Clinical Studies with Clevudine in Hepatitis B Infected Patients
Apr 20, 2009
|
12.5 KB |
|
| |
Company will increase focus on HCV pipeline
Conference call at 8:00 AM ET today
Princeton, NJ - (April 20, 2009) - Pharmasset, Inc. (Nasdaq: VRUS) announced today that after a discussion with its independent Data Safety Monitoring Board (DSMB) and the FDA, the company has decided to voluntarily t...
|
|
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
Mar 31, 2009
|
10.7 KB |
|
| |
PRINCETON, N.J., March 31, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV). Pharmasset filed an Inve...
|
|
Pharmasset to Present at Two Upcoming Investor Conferences
Mar 30, 2009
|
10.8 KB |
|
| |
PRINCETON, N.J., March 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the upcoming Citi Fourth Annual Biotech Day Conference and the Canaccord Adams Hepatitis C Conference. The Citi conference will be held in New York (April 1), while the Canaccord Adams conference wil...
|
|
Pharmasset to Present at Two Upcoming Investor Conferences
Mar 3, 2009
|
10.8 KB |
|
| |
PRINCETON, N.J., March 3, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Barclays Capital Global Healthcare Conference and the Cowen & Company 29th Annual Healthcare Conference. The Barclays conference will be held in the Loews Miami Beach Hotel, Miami, FL (March 10 to...
|
|
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Feb 9, 2009
|
16.3 KB |
|
| |
PRINCETON, N.J., Feb 09, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections, reported operational highlights and financial results for the fiscal quarter ended December 31, 2008....
|
|
Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
Jan 30, 2009
|
9.8 KB |
|
| |
PRINCETON, N.J., Jan 30, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that it has entered into definitive agreements dated January 29, 2009 with a select group of institutional investors to sell 4,678,000 shares of its common stock in a "registered direct" offering. The investors have agreed...
|
|
Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
Jan 12, 2009
|
12.3 KB |
|
| |
PRINCETON, N.J., Jan 12, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that they and their development partner, Roche, have agreed with the FDA on the final design for a phase 2b trial with R7128, a nucleoside inhibitor of hepatitis C (HCV), slated to initiate in the first quarter of this yea...
|
|
Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
Jan 8, 2009
|
10.5 KB |
|
| |
PRINCETON, N.J., Jan 08, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that management will present at the 27th Annual JPMorgan Healthcare Conference being held from January 12 to 15, 2009 at the Westin St Francis in San Francisco, CA. Schaefer Price, Pharmasset's President and Chief Executive Offi...
|
|
Pharmasset Reports Fiscal Year End 2008 Financial Results
Dec 11, 2008
|
15.8 KB |
|
| |
PRINCETON, N.J., Dec 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc.
(Nasdaq: VRUS), a clinical stage pharmaceutical company committed to
discovering, developing and commercializing novel drugs to treat viral
infections, reported financial results for the fiscal year ended September 30,
2008. At September 30, 2008, P...
|
|
Pharmasset to Present at Two Upcoming Investor Conferences
Nov 10, 2008
|
8.7 KB |
|
| |
PRINCETON, N.J., Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Rodman and Renshaw 10th Annual Global Investment Conference and the Lazard Capital Markets 5th Annual Healthcare Conference. Both conferences will be held in New York, NY.
Schaefer Price, Pharm...
|
|
Roche, InterMune and Pharmasset Announce Initiation of INFORM-1, the First Dual-Combination Clinical Trial with Oral Antivirals in Hepatitis C
Nov 10, 2008
|
11.9 KB |
|
| |
PRINCETON, N.J., Nov 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS), Roche (SWX: ROG) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patients have been dosed in an innovative clinical trial in patients chronically infected with the hepatitis C virus (HCV). The trial (run in centers in A...
|
|
Pharmasset to Webcast an Investor Event from the AASLD Meeting
Oct 28, 2008
|
9.6 KB |
|
| |
PRINCETON, N.J., Oct 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) today announced that it will webcast an investor event from the American Association for the Study of Liver Diseases (AASLD) on Sunday, November 2, 2008 starting at 5:30 PM PT. During this webcast, management will review Pharmasset's prog...
|
|
Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
Oct 8, 2008
|
6.3 KB |
|
| |
PRINCETON, N.J., Oct 08, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) management will present at the Natixis Bleichroeder Hidden Gems Conference being held from October 13-14, 2008 at the Waldorf Astoria in New York City. Michelle Berrey, Pharmasset's Chief Medical Officer, will provide an overview of the c...
|
|
Richard E.T. Smith, Ph.D. Joins Pharmasset as Vice President of Investor Relations and Corporate Communications
Oct 6, 2008
|
8.3 KB |
|
| |
PRINCETON, N.J., Oct 06, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces that Richard E.T. Smith, Ph.D., is joining the Company as Vice President of Investor Relations and Corporate Communications. Dr. Smith will be responsible for all investor relations functions and will report directly to Chief Fi...
|
|
|
= add release to Briefcase |
